Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy C Greiner

Showing results (61-70 of 127) with videos related to

Pageof 13
Sort By:
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 28, 2005
Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphomaChristine P Hans, Dennis D Weisenburger, Timothy C Greiner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2008
Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphomaKai Fu, Dennis D Weisenburger, William W L Choi, et al.
Blood|March 16, 2002
The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profileJames Z Huang, Warren G Sanger, Timothy C Greiner, et al.
British Journal of Haematology|April 23, 2013
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 casesAnamarija M Perry, David Crockett, Bhavana J Dave, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2010
Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximabPaul N Meyer, Kai Fu, Timothy C Greiner, et al.
Blood|August 9, 2013
Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphomaPaola Bonetti, Monica Testoni, Marta Scandurra, et al.
Human Pathology|November 25, 2017
Follicular large cleaved cell (centrocytic) lymphoma: an unrecognized variant of follicular lymphomaRadwa El Behery, Javier A Laurini, Dennis D Weisenburger, et al.
Blood|September 21, 2007
Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphomaKen H Young, Dennis D Weisenburger, Bhavana J Dave, et al.
Blood|December 8, 2009
Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphomaJaveed Iqbal, Dennis D Weisenburger, Timothy C Greiner, et al.
Leukemia & Lymphoma|April 2, 2015
Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcomeGabriel C Caponetti, Bhavana J Dave, Anamarija M Perry, et al.
Pageof 13

Showing results (61-70 of 127) with videos related to

Sort By:
Pageof 13
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 28, 2005
Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphomaChristine P Hans, Dennis D Weisenburger, Timothy C Greiner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2008
Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphomaKai Fu, Dennis D Weisenburger, William W L Choi, et al.
Blood|March 16, 2002
The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profileJames Z Huang, Warren G Sanger, Timothy C Greiner, et al.
British Journal of Haematology|April 23, 2013
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 casesAnamarija M Perry, David Crockett, Bhavana J Dave, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2010
Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximabPaul N Meyer, Kai Fu, Timothy C Greiner, et al.
Blood|August 9, 2013
Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphomaPaola Bonetti, Monica Testoni, Marta Scandurra, et al.
Human Pathology|November 25, 2017
Follicular large cleaved cell (centrocytic) lymphoma: an unrecognized variant of follicular lymphomaRadwa El Behery, Javier A Laurini, Dennis D Weisenburger, et al.
Blood|September 21, 2007
Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphomaKen H Young, Dennis D Weisenburger, Bhavana J Dave, et al.
Blood|December 8, 2009
Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphomaJaveed Iqbal, Dennis D Weisenburger, Timothy C Greiner, et al.
Leukemia & Lymphoma|April 2, 2015
Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcomeGabriel C Caponetti, Bhavana J Dave, Anamarija M Perry, et al.
Pageof 13